A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induc
Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM). It is easy to cause dry mouth and infection, which seriously affects the comfort and quality of life of patients. There are many pharm
| Condition(s) | Oral Mucositis in Head and Neck Cancer, Chemo-radiotherapy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM). It is easy to cause dry mouth and infection, which seriously affects the comfort and quality of life of patients. There are many pharmacological and non-pharmacological mouthwash solutions in clinical practice, the purpose of which is to reduce bacterial accumulation in order to prevent and improve OM. Olive oil has powerful moisturizing, antioxidant and anti-inflammatory properties. There is no research on the use of olive oil in the prevention or treatment of OM. Objective: The purpose of this study was to evaluate the preventive and therapeutic effects of olive oil as a mouthwash solution on OM caused by |
| Who can participate | Inclusion Criteria: * A. Aged 20 years or older. B. Diagnosed with a primary cancer located in the head and neck region and preparing to undergo radiotherapy or concurrent chemoradiotherapy (CCRT). For the purposes of this study, CCRT is defined as receiving chemotherapy within one week before or after the first day of radiotherapy. C. The total prescribed radiotherapy dose is between 6000 and 7200 cGy. D. Conscious and able to communicate in Mandarin or Taiwanese. E. Willing to participate in the study after receiving an explanation, and capable of signing the informed consent form. Exclusion Criteria: A. Patients diagnosed with recurrent head and neck cancer undergoing a second course of radiotherapy or CCRT. B. Patients who are allergic or have a history of allergy to any component of t |
| Ages | 20 Years |
| Sex | All |
| Lead sponsor | Chiayi Christian Hospital |
| Locations | Chiayi City, Chia-Yi City, Taiwan |
| Start date | 2022-12-04 |
| NCT ID | NCT07293013 |
| Official listing | https://clinicaltrials.gov/study/NCT07293013 |